logo

For the Inventor, By the Inventor

Ladenburg, Germany

Heidelberg Pharma Research Gmbh


USPTO Granted Patents = 20


Trademarks = 1

Forward Citations = 1

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Torsten Hechler (13 out of 15 patents)

silverMedal Werner Simon (13 out of 20 patents)

bronzeMedal Michael Kulke (12 out of 13 patents)

4.  Christian Lutz (11 out of 14 patents)

5.  Susanne Werner-Simon (10 out of 10 patents)

6.  Christoph Müller (8 out of 11 patents)

7.  Andreas Pahl (7 out of 12 patents)

8.  Christoph Mueller (4 out of 7 patents)

9.  Michael P Cooke (3 out of 21 patents)

10.  Anthony Boitano (3 out of 21 patents)

11.  Francesca Gallo (3 out of 3 patents)

12.  Jan Anderl (2 out of 7 patents)

13.  Roderich Süssmuth (2 out of 4 patents)

14.  Caroline Knittel (2 out of 2 patents)

15.  Mary-Ann Siegert (2 out of 2 patents)


20 patents:

1. 12655179 - Synthesis of amanin and its derivatives (2026-06-16),
2. 12595284 - AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF (2026-04-07),
3. 12576158 - Antibody drug conjugates with cleavable linkers (2026-03-17),
4. 12544419 - TARGETED AMATOXIN CONJUGATE FOR THE TREATMENT OF SOLID TUMORS (2026-02-10),
5. 12403201 - B-lymphocyte specific amatoxin antibody conjugates (2025-09-02),
6. 12403185 - Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy (2025-09-02),
7. 12378196 - Synthesis of (S)-6-hydroxytryptophan and derivatives thereof (2025-08-05),
8. 12251448 - Compositions and methods for the depletion of CD5+ cells (2025-03-18),
9. 12201693 - Amanitin conjugates (2025-01-21),
10. 12006370 - Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy (2024-06-11),
11. 11976131 - Humanized antibodies against PSMA (2024-05-07),
12. 11926631 - Method of treating cancer using amanitin derivatives (2024-03-12),
13. 11702451 - Method for synthesizing amanitins (2023-07-18),
14. 11590238 - Amanitin conjugates (2023-02-28),
15. 11584708 - Synthesis of (2S,3R,4R)-4,5-dihydroxyisoleucine and derivatives (2023-02-21),
Company Overview
Heidelberg Pharma Research GmbH is a biotechnology company based in Ladenburg, Germany, specializing in the development of innovative therapies for cancer treatment. The company focuses on antibody-drug conjugates (ADCs), leveraging its proprietary technology to enhance the efficacy and safety of cancer therapeutics. With a commitment to advancing targeted therapies, Heidelberg Pharma aims to address unmet medical needs in oncology through its cutting-edge research and development efforts.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

20 Patents

#3 in Ladenburg

#2,216 in Germany

#31,233 in the World

Ladenburg, DE
Ladenburg, Germany

Heidelberg Pharma Research Gmbh

Forward Citations = 1

25 inventors:

goldMedal Torsten Hechler (13 out of 15 patents)

silverMedal Werner Simon (13 out of 20 patents)

bronzeMedal Michael Kulke (12 out of 13 patents)

4.  Christian Lutz (11 out of 14 patents)

5.  Susanne Werner-Simon (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Heidelberg Pharma Research Gmbh. Retrieved from https://idiyas.com/company/heidelberg-pharma-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…